Capricor Therapeutics (CAPR) Stock Forecast, Price Target & Predictions
CAPR Stock Forecast
Capricor Therapeutics stock forecast is as follows: an average price target of $35.75 (represents a 94.50% upside from CAPR’s last price of $18.38) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
CAPR Price Target
The average price target for Capricor Therapeutics (CAPR) is $35.75 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $43.00 to $25.00. This represents a potential 94.50% upside from CAPR's last price of $18.38.
CAPR Analyst Ratings
According to 6 Wall Street analysts, Capricor Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for CAPR stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Capricor Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 21, 2024 | Edward Tenthoff | Piper Sandler | $35.00 | $18.86 | 85.58% | 90.42% |
| Oct 14, 2024 | Leland Gershall | Oppenheimer | $43.00 | $17.77 | 141.98% | 133.95% |
| Sep 25, 2024 | Jason McCarthy | Maxim Group | $25.00 | $9.10 | 174.73% | 36.02% |
| Sep 25, 2024 | Joseph Pantginis | H.C. Wainwright | $40.00 | $11.12 | 259.71% | 117.63% |
| Sep 17, 2024 | Leland Gershall | Oppenheimer | $15.00 | $5.08 | 195.28% | -18.39% |
| May 16, 2024 | Leland Gershall | Oppenheimer | $14.00 | $5.64 | 148.23% | -23.83% |
The latest Capricor Therapeutics stock forecast, released on Oct 21, 2024 by Edward Tenthoff from Piper Sandler, set a price target of $35.00, which represents a 85.58% increase from the stock price at the time of the forecast ($18.86), and a 90.42% increase from CAPR last price ($18.38).
Capricor Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 5 | 6 |
| Avg Price Target | $35.00 | $31.60 | $28.67 |
| Last Closing Price | $18.38 | $18.38 | $18.38 |
| Upside/Downside | 90.42% | 71.93% | 55.98% |
In the current month, the average price target of Capricor Therapeutics stock is $35.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 90.42% increase as opposed to Capricor Therapeutics's last price of $18.38. This month's average price target is up 10.76% compared to last quarter, and up 22.08% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 21, 2024 | Piper Sandler | - | Overweight | Initialise |
| Oct 14, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Oct 11, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 25, 2024 | Maxim Group | Buy | Buy | Hold |
| Sep 24, 2024 | Cantor Fitzgerald | Overweight | Overweight | Hold |
| Sep 20, 2024 | Oppenheimer | Buy | Buy | Hold |
| Sep 18, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 17, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Jul 02, 2024 | Oppenheimer | Buy | Buy | Hold |
| Jul 02, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Capricor Therapeutics's last stock rating was published by Piper Sandler on Oct 21, 2024. The company Initialise its CAPR rating from "null" to "Overweight".
Capricor Therapeutics Financial Forecast
Capricor Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Sep 21 | Jun 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | Sep 14 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $12.09M | $6.19M | $3.92M | $2.99M | $957.35K | $1.59M | - | - | $204.08K | $57.83K | $16.86K | $49.86K | $185.69K | $222.10K | $142.07K | $410.35K | $230.50K | $400.07K | $880.81K | $1.22M | $1.79M | $1.30M |
| Avg Forecast | $6.22M | $2.17M | $2.17M | $2.17M | $9.82M | $4.28M | $4.58M | $9.70M | $10.60M | $3.15M | $3.00M | $1.00M | $10.00K | $420.00K | $390.00K | $210.00K | $210.00K | $210.00K | $210.00K | $210.00K | $210.00K | $70.00K | $220.00K | $220.00K | $430.00K | $342.86K | $776.47K | $891.54K | $1.58M | $2.20M |
| High Forecast | $8.55M | $2.98M | $2.98M | $2.89M | $14.03M | $4.38M | $6.30M | $13.34M | $14.58M | $4.33M | $4.13M | $1.38M | $13.76K | $420.00K | $390.00K | $210.00K | $210.00K | $210.00K | $210.00K | $210.00K | $210.00K | $70.00K | $220.00K | $220.00K | $430.00K | $411.43K | $931.76K | $1.07M | $1.90M | $2.64M |
| Low Forecast | $4.34M | $1.51M | $1.51M | $1.44M | $7.22M | $4.18M | $3.19M | $6.76M | $7.39M | $2.20M | $2.09M | $697.35K | $6.97K | $420.00K | $390.00K | $210.00K | $210.00K | $210.00K | $210.00K | $210.00K | $210.00K | $70.00K | $220.00K | $220.00K | $430.00K | $274.28K | $621.17K | $713.23K | $1.26M | $1.76M |
| # Analysts | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 11 | 15 | 9 | 9 | 8 | 8 | 12 | 16 | 19 | 8 | 11 | 11 | 11 |
| Surprise % | - | - | - | - | - | - | - | - | 1.14% | 1.96% | 1.31% | 2.99% | 95.74% | 3.79% | - | - | 0.97% | 0.28% | 0.08% | 0.24% | 0.88% | 3.17% | 0.65% | 1.87% | 0.54% | 1.17% | 1.13% | 1.36% | 1.13% | 0.59% |
Capricor Therapeutics's average Quarter revenue forecast for Mar 24 based on 1 analysts is $9.70M, with a low forecast of $6.76M, and a high forecast of $13.34M. CAPR's average Quarter revenue forecast represents a -19.76% decrease compared to the company's last Quarter revenue of $12.09M (Dec 23).
Capricor Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Sep 21 | Jun 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | Sep 14 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 11 | 15 | 9 | 9 | 8 | 8 | 12 | 16 | 19 | 8 | 11 | 11 | 11 |
| EBITDA | - | - | - | - | - | - | - | - | $-1.06M | $-6.86M | $-8.13M | $-8.60M | $-8.41M | $-6.45M | $-7.34M | $-3.87M | $-4.70M | $-4.14M | $-3.87M | $-3.45M | $-2.05M | $-1.43M | $-1.56M | $-2.00M | $-2.48M | $-3.64M | $-3.52M | $-4.17M | $-3.39M | $-1.47M |
| Avg Forecast | $-6.11M | $-2.13M | $-2.13M | $-2.13M | $-9.65M | $-4.21M | $-4.50M | $-9.53M | $-10.42M | $-3.10M | $-2.95M | $-982.77K | $-9.83K | $-412.76K | $-383.28K | $-206.38K | $-5.10M | $-206.38K | $-206.38K | $-206.38K | $-2.24M | $-68.79K | $-216.21K | $-2.53M | $-422.59K | $-3.03M | $-3.05M | $-2.63M | $-2.94M | $-1.87M |
| High Forecast | $-4.26M | $-1.48M | $-1.48M | $-1.42M | $-7.10M | $-4.11M | $-3.14M | $-6.65M | $-7.26M | $-2.16M | $-2.06M | $-685.34K | $-6.85K | $-412.76K | $-383.28K | $-206.38K | $-4.08M | $-206.38K | $-206.38K | $-206.38K | $-1.79M | $-68.79K | $-216.21K | $-2.02M | $-422.59K | $-2.42M | $-2.44M | $-2.11M | $-2.36M | $-1.49M |
| Low Forecast | $-8.40M | $-2.93M | $-2.93M | $-2.84M | $-13.78M | $-4.30M | $-6.19M | $-13.11M | $-14.33M | $-4.26M | $-4.06M | $-1.35M | $-13.52K | $-412.76K | $-383.28K | $-206.38K | $-6.13M | $-206.38K | $-206.38K | $-206.38K | $-2.69M | $-68.79K | $-216.21K | $-3.04M | $-422.59K | $-3.64M | $-3.66M | $-3.16M | $-3.53M | $-2.24M |
| Surprise % | - | - | - | - | - | - | - | - | 0.10% | 2.22% | 2.76% | 8.75% | 855.99% | 15.62% | 19.16% | 18.74% | 0.92% | 20.04% | 18.77% | 16.72% | 0.92% | 20.74% | 7.23% | 0.79% | 5.86% | 1.20% | 1.15% | 1.58% | 1.15% | 0.79% |
undefined analysts predict CAPR's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Capricor Therapeutics's previous annual EBITDA (undefined) of $NaN.
Capricor Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Sep 21 | Jun 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | Sep 14 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 11 | 15 | 9 | 9 | 8 | 8 | 12 | 16 | 19 | 8 | 11 | 11 | 11 |
| Net Income | - | - | - | - | - | - | - | - | $-762.09K | $-6.39M | $-7.37M | $408.67M | $-7.83M | $-6.26M | $-6.90M | $-3.93M | $-4.75M | $-4.18M | $-3.91M | $-3.48M | $-2.08M | $-1.47M | $-1.61M | $-2.05M | $-2.52M | $-3.67M | $-3.67M | $-4.27M | $-3.48M | $-1.54M |
| Avg Forecast | $-10.48M | $-12.79M | $-13.02M | $-9.46M | $-7.28M | $-11.86M | $-11.78M | $-3.76M | $-2.98M | $-10.04M | $-11.58M | $-10.59M | $-11.25M | $-10.19M | $-8.12M | $-7.32M | $-5.16M | $-6.37M | $-5.73M | $-10.83M | $-2.27M | $-10.83M | $-21.65M | $-2.58M | $-35.03M | $-3.06M | $-3.18M | $-2.69M | $-3.02M | $-1.96M |
| High Forecast | $-6.36M | $-7.76M | $-7.89M | $-7.29M | $-7.04M | $-7.19M | $-7.15M | $-2.28M | $-1.81M | $-6.09M | $-7.03M | $-6.42M | $-6.82M | $-10.19M | $-8.12M | $-7.32M | $-4.13M | $-6.37M | $-5.73M | $-10.83M | $-1.82M | $-10.83M | $-21.65M | $-2.07M | $-35.03M | $-2.45M | $-2.54M | $-2.16M | $-2.42M | $-1.57M |
| Low Forecast | $-15.60M | $-19.04M | $-19.37M | $-11.62M | $-7.52M | $-17.65M | $-17.53M | $-5.60M | $-4.43M | $-14.94M | $-17.24M | $-15.76M | $-16.74M | $-10.19M | $-8.12M | $-7.32M | $-6.19M | $-6.37M | $-5.73M | $-10.83M | $-2.73M | $-10.83M | $-21.65M | $-3.10M | $-35.03M | $-3.67M | $-3.81M | $-3.23M | $-3.62M | $-2.35M |
| Surprise % | - | - | - | - | - | - | - | - | 0.26% | 0.64% | 0.64% | -38.59% | 0.70% | 0.61% | 0.85% | 0.54% | 0.92% | 0.66% | 0.68% | 0.32% | 0.92% | 0.14% | 0.07% | 0.79% | 0.07% | 1.20% | 1.15% | 1.58% | 1.15% | 0.79% |
Capricor Therapeutics's average Quarter net income forecast for Jun 23 is $-11.58M, with a range of $-17.24M to $-7.03M. CAPR's average Quarter net income forecast represents a -102.83% decrease compared to the company's last Quarter net income of $408.67M (Mar 23).
Capricor Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Sep 21 | Jun 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | Sep 14 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 11 | 15 | 9 | 9 | 8 | 8 | 12 | 16 | 19 | 8 | 11 | 11 | 11 |
| SG&A | - | - | - | - | - | - | - | - | $3.21M | $3.02M | $2.85M | $3.51M | $2.79M | $2.56M | $2.36M | $1.80M | $1.79M | $1.49M | $1.30M | $1.61M | $1.14M | $876.72K | $911.97K | $831.93K | $976.49K | $1.39M | $1.19M | $1.08M | $1.40M | $819.68K |
| Avg Forecast | $71.01M | $24.75M | $24.75M | $24.75M | $112.15M | $48.91M | $52.32M | $110.80M | $121.08M | $35.98M | $34.27M | $11.42M | $114.23K | $4.80M | $4.45M | $2.40M | $2.40M | $2.40M | $2.40M | $2.40M | $2.40M | $799.59K | $2.51M | $2.51M | $4.91M | $3.92M | $8.87M | $685.07K | $1.21M | $1.04M |
| High Forecast | $97.69M | $34.05M | $34.05M | $33.00M | $160.21M | $50.03M | $71.97M | $152.42M | $166.57M | $49.50M | $47.14M | $15.71M | $157.13K | $4.80M | $4.45M | $2.40M | $2.40M | $2.40M | $2.40M | $2.40M | $2.40M | $799.59K | $2.51M | $2.51M | $4.91M | $4.70M | $10.64M | $822.09K | $1.45M | $1.25M |
| Low Forecast | $49.52M | $17.26M | $17.26M | $16.50M | $82.51M | $47.79M | $36.48M | $77.27M | $84.44M | $25.09M | $23.90M | $7.97M | $79.65K | $4.80M | $4.45M | $2.40M | $2.40M | $2.40M | $2.40M | $2.40M | $2.40M | $799.59K | $2.51M | $2.51M | $4.91M | $3.13M | $7.10M | $548.06K | $969.83K | $831.61K |
| Surprise % | - | - | - | - | - | - | - | - | 0.03% | 0.08% | 0.08% | 0.31% | 24.46% | 0.53% | 0.53% | 0.75% | 0.75% | 0.62% | 0.54% | 0.67% | 0.47% | 1.10% | 0.36% | 0.33% | 0.20% | 0.35% | 0.13% | 1.58% | 1.15% | 0.79% |
Capricor Therapeutics's average Quarter SG&A projection for Mar 24 is $110.80M, based on 1 Wall Street analysts, with a range of $77.27M to $152.42M. The forecast indicates a 3350.70% rise compared to CAPR last annual SG&A of $3.21M (Dec 23).
Capricor Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Sep 21 | Jun 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | Sep 14 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 11 | 15 | 9 | 9 | 8 | 8 | 12 | 16 | 19 | 8 | 11 | 11 | 11 |
| EPS | - | - | - | - | - | - | - | - | $-0.02 | $-0.25 | $-0.29 | $16.19 | $-0.31 | $-0.26 | $-0.28 | $-0.17 | $-0.21 | $-0.21 | $-0.20 | $-0.23 | $-0.30 | $-0.34 | $-0.43 | $-0.59 | $-0.80 | $-1.40 | $-1.70 | $-2.60 | $-2.30 | $-1.30 |
| Avg Forecast | $-0.32 | $-0.39 | $-0.39 | $-0.29 | $-0.22 | $-0.36 | $-0.36 | $-0.11 | $-0.09 | $-0.30 | $-0.35 | $-0.32 | $-0.34 | $-0.32 | $-0.26 | $-0.23 | $-0.23 | $-0.20 | $-0.18 | $-0.34 | $-0.36 | $-0.34 | $-0.68 | $-0.80 | $-1.10 | $-1.00 | $-0.13 | $-0.12 | $-0.12 | $-0.28 |
| High Forecast | $-0.19 | $-0.23 | $-0.24 | $-0.22 | $-0.21 | $-0.22 | $-0.22 | $-0.07 | $-0.05 | $-0.18 | $-0.21 | $-0.19 | $-0.21 | $-0.32 | $-0.26 | $-0.23 | $-0.23 | $-0.20 | $-0.18 | $-0.34 | $-0.36 | $-0.34 | $-0.68 | $-0.80 | $-1.10 | $-0.80 | $-0.10 | $-0.10 | $-0.10 | $-0.22 |
| Low Forecast | $-0.47 | $-0.58 | $-0.59 | $-0.35 | $-0.23 | $-0.53 | $-0.53 | $-0.17 | $-0.13 | $-0.45 | $-0.52 | $-0.48 | $-0.51 | $-0.32 | $-0.26 | $-0.23 | $-0.23 | $-0.20 | $-0.18 | $-0.34 | $-0.36 | $-0.34 | $-0.68 | $-0.80 | $-1.10 | $-1.20 | $-0.16 | $-0.14 | $-0.15 | $-0.33 |
| Surprise % | - | - | - | - | - | - | - | - | 0.28% | 0.82% | 0.83% | -50.59% | 0.91% | 0.81% | 1.10% | 0.74% | 0.91% | 1.05% | 1.11% | 0.68% | 0.83% | 1.00% | 0.63% | 0.74% | 0.73% | 1.40% | 13.08% | 21.67% | 19.17% | 4.64% |
According to 1 Wall Street analysts, Capricor Therapeutics's projected average Quarter EPS for Jun 23 is $-0.35, with a low estimate of $-0.52 and a high estimate of $-0.21. This represents a -102.16% decrease compared to CAPR previous annual EPS of $16.19 (Mar 23).
Capricor Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| AKTX | Akari Therapeutics | $2.29 | $12.00K | 523917.47% | - |
| ONTX | Traws Pharma | $1.00 | $7.00 | 600.00% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| ANAB | AnaptysBio | $18.88 | $52.00 | 175.42% | Buy |
| NXTC | NextCure | $1.29 | $3.00 | 132.56% | Buy |
| CAPR | Capricor Therapeutics | $18.38 | $35.75 | 94.50% | Buy |
| KROS | Keros Therapeutics | $54.01 | $102.60 | 89.96% | Buy |
| IDYA | IDEAYA Biosciences | $26.19 | $46.58 | 77.85% | Buy |
| CDTX | Cidara Therapeutics | $14.96 | $24.00 | 60.43% | Buy |
| MGTX | MeiraGTx | $6.09 | $9.00 | 47.78% | Buy |
| SLNO | Soleno Therapeutics | $51.64 | $76.00 | 47.17% | Buy |